Navigation Links
Anthera Announces Conference Call to Discuss Analytical Method and Timing of Upcoming VISTA-16 Biomarker Analysis
Date:2/23/2011

HAYWARD, Calif., Feb. 23, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it will hold a conference call to discuss the analytical method of the upcoming VISTA-16 interim biomarker analysis and the expected timeline of the results.Conference Call Access:Date:

February 28, 2011Time:

5:00 pm Eastern TimeDomestic Dial-in:

(877) 312-8807International Dial-in:

(253) 237-1190Conference ID:

45608522To access the 24-hour audio replay, U.S. and Canadian participants may dial (800) 642-1687; international participants may dial (706) 645-9291.  The conference ID for the replay is 45608522. The audio replay will be available until March 7, 2011.  This conference call will be webcast live and archived on Anthera's website until February 28, 2012, www.anthera.com.  

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has one Phase 3 clinical program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease (CAD). Anthera's Phase 2 product candidate, A-623, targets elevated levels of B-lymphocyte stimulator (BAFF) which has been associated with a variety of B-Cell mediated autoimmune diseases, including systemic lupus erythematosus, or lupus. For more informat
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
2. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
3. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
5. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
6. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
7. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
9. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
10. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
11. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Thoratec Corporation (NASDAQ: THOR ), ... to save, support and restore failing hearts, said today ... Global Healthcare Conference on Wednesday, September 10. ... Officer, will provide an update on the company, beginning ... Daylight Time).   A webcast of the ...
(Date:8/29/2014)... 29, 2014 According to ... by Extraction type (SFE, Cold Pressed, Organic Solvent, & ... Pharmaceutical, Food Supplements, Fragrance, & Others) - Global Trends ... and segments the Amaranth Seed Oil Market with ... in terms of value. The Amaranth Seed Oil ...
(Date:8/29/2014)... According to the new ... (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User (Research, ... Synthesis, NGS, DNA, RNAi) - Global Forecast to ... Market is expected to reach $1,712.1 Million by ... a CAGR of 9.8% from 2014 to 2019.. ...
Breaking Medicine Technology:Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4
... and IRVINE, Calif., May 6, 2011 CryoLife, Inc. ... device and cardiovascular tissue processing company, today announced the ... through its wholly owned subsidiary CL Falcon, Inc., for ... ("Cardiogenesis") (OTCQB: CGCP).  The tender offer expired at 12:00 ...
... The Female Health Company (NASDAQ-CM: FHCO) today announced ... Comercio (Semina), was successful in a public tender to ... to 20 million FC2 Female Condoms.  The contract is ... will be determined at the Ministry of Health,s discretion. ...
Cached Medicine Technology:CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation 2CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation 3CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation 4CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation 5CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation 6The Female Health Company's Brazilian Distributor, Semina, Awarded Contract For Up To 20 Million FC2 Female Condoms 2The Female Health Company's Brazilian Distributor, Semina, Awarded Contract For Up To 20 Million FC2 Female Condoms 3
(Date:8/30/2014)... 2014 Hands On Mobile ... offers the complete spa experience combining elegant decor, ... the most important ingredient of all, states Marla ... pro's! People will enjoy the get-away feel, without ... website reads, "Step into the spacious, luxurious spa ...
(Date:8/30/2014)... 2014 Daily Gossip magazine reveals in ... and panic attacks under control with a simple and ... describes this new method as an anxiety recovery ... and overcome general anxiety related disorders. , What ... fact that it can be accessed by users from ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 The ... Nutrition and Pharameuticals. Nutraceuticals is a source of ... ingredients from natural food sources. Nutraceutical ingredients have ... to the human body. Nutraceutical health products include ... fortified foods and more. Although nature is the ...
(Date:8/30/2014)... Hicksville, NY (PRWEB) August 30, 2014 ... Organizations throughout the planet has been one of ... in order to create a positive impact around ... aesthetics and staffed with top trained executives and ... millions of people worldwide. Vital statistics demonstrate ...
(Date:8/30/2014)... TX (PRWEB) August 30, 2014 ... Disruptor Industry, 2009-2019 is a professional and in-depth ... industry. The report firstly reviews the basic information ... manufacturing technology. The report then explores global and ... product specification, capacity, Production value, and market share ...
Breaking Medicine News(10 mins):Health News:Hands On Mobile Massage and Spa of Long Island Now Offers a Spa-on-wheels 2Health News:Panic Away Review Reveals New Natural Remedy for Anxiety Patients 2Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 2Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 3Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 4Health News:Cradle of Aviation Museum Opens Its Doors to Long Island Scientologists 2Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 2Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 3Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 4
... The earliest known case of coronary artery disease has been ... lived between 1580 and 1550 B.C., and died in her ... scans found that this wasn,t a unique case. About 45 ... an accumulation of plaque in arteries. The findings ...
... a genetic characteristic of metastatic prostate cancer that defines ... published in Cancer Discovery , the newest journal ... debut at the AACR 102nd Annual Meeting 2011, held ... an investigator of the Howard Hughes Medical Institute and ...
... laboratory and epidemiologic data to find that men using the ... prostate cancer. The scientists say further research about the ... ones that work the same way, to treat the cancer. ... for centuries in folk medicine and for decades to treat ...
... bladder cancer risk and to the length of protective caps ... of Texas MD Anderson Cancer Center reported today at the ... telomeres, guard against chromosomal damage and genomic instability that can ... single point of variation in the genome strongly associated with ...
... use has been linked to thicker arteries, possibly contributing to ... of twin veterans. The data is being presented Tuesday, April ... Orleans. Depression can heighten the risk for heart disease, ... is separate and independent from depression itself, says first author ...
... hedgehog pathway inhibitor demonstrated efficacy in preventing and treating ... syndrome, a rare inheritable disease, according to Phase II ... held April 2-6. In 1996, Ervin Epstein Jr., ... Institute, and colleagues identified the site of the mutation ...
Cached Medicine News:Health News:Mummies Show Heart Disease Is an Ancient Problem 2Health News:Heart drug cuts prostate cancer risk; holds potential for therapeutic use 2Health News:Heart drug cuts prostate cancer risk; holds potential for therapeutic use 3Health News:Genetic variation cuts bladder cancer risk, protects chromosome tips 2Health News:Genetic variation cuts bladder cancer risk, protects chromosome tips 3Health News:Antidepressants linked to thicker arteries 2Health News:New inhibitor prevented lesions, reduced tumor size in basal cell cancer 2Health News:New inhibitor prevented lesions, reduced tumor size in basal cell cancer 3
Used for stone manipulation and removal in the urinary tract. The hollow shaft allows protected delivery of a laser fiber to an entrapped stone for fragmentation of the stone. Supplied sterile in pee...
... Tipless Design, ZeroTip basket features ... negotiation and close stone approximation., Flexible ... deflection for efficient retrieval of calyceal ... passed through a 3.6Fr working channel, ...
... Tip 12 Inch , 20 inch,PVC, Length ... Available in 3,4,5 6Fr. These top quality ... flexible polymer material and have standard screw ... They are manufactured to the highest standards. ...
Bard Coude-Tip Latex Urethral Catheter, Two Eyes (Tiemann Model)...
Medicine Products: